Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vamorolone CYP3A4 induction study with midazolam in healthy subjects
NCT06689527Phase 1Completed
- Sponsor
- Santhera Pharmaceuticals
- Start
- Aug 2024
- Primary completion
- Sep 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vamorolone, sponsored by Santhera Pharmaceuticals. Primary endpoints: Area Under the Curve from Time Zero to Last Measurable Concentration of Midazolam at Day 14, Area Under the Curve from Time Zero to Infinity of Midazolam at Day 14 and 4 more. Started Aug 2024; status: completed.
02
Drugs
vamorolone
Beyond the preview
Go deeper on NCT06689527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06689527.